Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

Published:2016-08-01 Issue:4 Volume:175 Page:668-672
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Gleeson Mary¹,Hawkes Eliza A.²³,Cunningham David¹,Chadwick Nick⁴,Counsell Nicholas⁴,Lawrie Anthony⁴,Jack Andrew⁵,Smith Paul⁴,Mouncey Paul⁴,Pocock Christopher⁶,Ardeshna Kirit M.⁷⁸,Radford John⁹,McMillan Andrew¹⁰,Davies John¹¹,Turner Deborah¹²,Kruger Anton¹³,Johnson Peter W.M.¹⁴,Gambell Joanna⁴,Linch David⁷

Affiliation:

1. The Royal Marsden Hospital; London and Surrey UK

2. Department of Oncology and Clinical Haematology; Austin Health; Heidelberg Melbourne Australia

3. Eastern Health; Melbourne Australia

4. Cancer Research UK and UCL Cancer Trials Centre; UCL Cancer Institute; London UK

5. HMDS; Leeds Teaching Hospitals NHS Trust; Leeds UK

6. East Kent Hospitals; Canterbury UK

7. University College London; London UK

8. Mount Vernon Cancer Centre; Northwood UK

9. The University of Manchester and the Christie NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester UK

10. Nottingham City Hospital; Nottingham UK

11. Western General Hospital; Edinburgh UK

12. Torbay Hospital; Torquay UK

13. Royal Cornwall Hospital; Truro UK

14. Cancer Research UK Centre; Southampton UK

Funder

Cancer Research UK

National Health Service (NHS)

National Institute for Health Research

University College London

Royal Marsden Hospital/Institute of Cancer Research

Chugai Pharmaceuticals

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14287/fullpdf

Reference14 articles.

1. Report of an International workshop to standardize response criteria for non-Hodgkin's lymphomas;Cheson;Journal of Clinical Oncology,1999

2. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles;Cunningham;Lancet,2013

3. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma;Dunleavy;New England Journal of Medicine,2013

4. Modelling of chemotherapy: the effective dose approach;Hasenclever;Annals of Hematology,2001

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital;Clinical Lymphoma Myeloma and Leukemia;2024-01

2. Updates in the Management of Primary Mediastinal B Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial;HemaSphere;2023-07

4. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era;Hematological Oncology;2022-12-08

5. Interim results of the PML-16, PML-19 protocols for primary mediastinal large B-cell lymphoma therapy;Russian journal of hematology and transfusiology;2022-10-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3